New York, USA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Dry Eye Disease Market to Register Immense Growth During the Study Period (2019–2032), Estimates DelveInsight | Leading...
The FDA approved Novartis AG's (NYSE: NVS) Fabhalta (iptacopan) as the first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is an acquired...
New York, USA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Tendinopathy Market to Register Incremental Growth During the Study Period (2019–2032), Estimates DelveInsight | Leading...
Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment...
Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology,...
New York, USA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Complement 3 Glomerulopathy Market to Witness an Upsurge in Growth by 2023, Predicts DelveInsight | Key Companies to Watch -...
New York, USA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spinal Muscular Atrophy Market to Grow Rapidly During the Forecast Period (2019–2032), Assesses DelveInsight | Key Players -...
Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patients with IgA nephropathy (IgAN). IgAN...